Editas Medicine, Inc. Inducement Stock Option AgreementInducement Stock Option Agreement • February 28th, 2024 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
EDITAS MEDICINE, INC. NONSTATUTORY STOCK OPTION AGREEMENTNonstatutory Stock Option Agreement • February 28th, 2024 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
EDITAS MEDICINE, INC. RESTRICTED STOCK UNIT AGREEMENTRestricted Stock Unit Agreement • February 28th, 2024 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
EDITAS MEDICINE, INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • February 28th, 2024 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
EDITAS MEDICINE, INC. Restricted Stock AgreementRestricted Stock Agreement • February 28th, 2024 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
This Restricted Stock Agreement (this “Agreement”) is made as of the Grant Date set forth below between Editas Medicine, Inc., a Delaware corporation (the “Company”), and the Participant named below.
OMNIBUS AMENDMENTOmnibus Amendment • February 28th, 2024 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Omnibus Amendment (the “Amendment”) is entered into as of February 5, 2024 (the “Amendment Effective Date”), by and between on the one hand, President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (“Harvard”) and The Broad Institute, Inc., a non-profit Massachusetts corporation, with a principal office at 415 Maine Street, Cambridge, MA 02142 (“Broad”) and on the other hand Editas Medicine, Inc., a Delaware corporation, located at 11 Hurley Street, Cambridge, MA 02141 (“Editas”), and amends (i) that certain Amended and Restated Cas9-I License Agreement, dated December 16, 2016 as has been amended from time to time, (the “Cas9-I Agreement”), (ii) that certain Cpf1 License Agreement, dated as of December 16, 2016 as has been amended from time to time, (the
EDITAS MEDICINE, INC. INDUCEMENT RESTRICTED STOCK UNIT AGREEMENTInducement Restricted Stock Unit Agreement • February 28th, 2024 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
